Solving the Capacity Crisis for Viral Vector Manufacturing

Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.

Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.

Participants will learn:

  1. The manufacturing challenges facing the viral vector industry
  2. The advantages of an integrated manufacturing solution
  3. How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom

 

 

 

Moderator

 

 

Charlotte Masy

Clive Glover

 

Director, Cell & Gene Therapy
Pall Biotech

 

 

 

Presenters

 

 

 

Charlotte Masy

Jeremy Rautenbach

 

Global Product Manager, Integrated Solutions
Pall Biotech

Charlotte Masy

Joseph Rininger

 

Director, Cell & Gene Therapy
Latham BioPharm Group

Charlotte Masy

Peter Makowensky

 

Director, Sales Engineering

G-CON Manufacturing

Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing

Listen to Podcast Today

More Biotech lblwebinar
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
July 2020
Accelerate Your Upstream Bioprocess (AsiaPac)

Biotech | Pall Corporation webinar series

What does it take to get a new biotech drug to market? The process development starts with culturing cells and requires the right technology to reliably and efficiently produce them. The capability to seamlessly move out of process development, into clinical trials, and from small to large-scale cGMP manufacturing, is essential.
 

Bioreactors have long been a critical part of the cell culture process, and presented challenges when it comes to moving from PD to cGMP manufacture. The first single-use bioreactors were introduced around 25 years ago. Since then, the evolution of single-use technology has brought many benefits, such as closed gamma irradiated biocontainers and scalable systems. As a result, single-use bioreactors are increasingly used for small-scale, mid-scale and large-scale production runs.
 

In this webinar, we will present case studies illustrating the benefits of leveraging industry experts, proven methods, and integrated upstream solutions to design a robust, scalable and reproducible process.
 

Participants will learn:

  • Strategies for transferring scalable processes from pre-clinical to cGMP commercial manufacturing
  • How partnering with Pall’s Accelerator℠ process development services team will help reduce time to market
  • Innovative single-use bioreactors whether you are growing adherent or suspension cells
Register